Home LiteratureArticle Details
PMID: 6149306 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: relevance to neurological symptoms in clinical syndromes with reduced brain dopamine.

The Journal of pharmacology and experimental therapeutics ·Vol. 231 ·No. 2 ·1984-11-00 ·Pages 343-54

Breese GR, Baumeister AA, McCown TJ, Emerick SG, Frye GD, Crotty K, Mueller RA

Abstract

Administration of L-dopa or apomorphine to neonatal and adult 6-hydroxydopamine (6-OHDA)-treated rats resulted in different behavioral responses depending on the age at which dopaminergic fibers were destroyed. When neonatal 6-OHDA-treated rats were tested as adults, they exhibited marked stereotypies, self-biting and self-mutilation behavior (SMB) when given these dopamine agonists. Self-biting as well as the incidence of SMB in neonatal 6-OHDA-treated rats showed dose-related changes between 10 and 100 mg/kg of L-dopa. This SMB and self-biting after L-dopa was observed as early as 22 to 24 days of age. Adult 6-OHDA-treated rats did not exhibit SMB or self-biting to L-dopa (100 mg/kg) or apomorphine (10 mg/kg), but did display paw treading and head nodding--behaviors not observed in neonatal 6-OHDA-treated rats. In addition, the locomotor response to apomorphine (1 mg/kg) was significantly greater in adult 6-OHDA-treated rats than in neonatal 6-OHDA-treated rats. Brain dopamine was reduced markedly in striatum, nucleus accumbens and olfactory tubercles in both 6-OHDA treatment groups with the reduction being slightly greater in rats treated with 6-OHDA neonatally. Serotonin content was elevated in striatum of rats treated neonatally with 6-OHDA, but not in adult 6-OHDA-treated rats. SMB and behaviors observed after L-dopa in rats treated neonatally with 6-OHDA were not apparent after L-dopa in rats with brain serotonin or norepinephrine reduced. Rats with brain dopaminergic fibers destroyed neonatally exhibited self-biting and SMB after L-dopa, suggesting that neonatal reduction of this amine is responsible for the SMB and self-biting in neonatal 6-OHDA-treated rats. 5-Hydroxytryptophan administration to neonatal 6-OHDA-treated rats did not induce SMB, indicating that release of serotonin by L-dopa is not responsible for this behavior. Because inhibition of dopamine-beta-hydroxylase did not alter the SMB response to L-dopa observed in neonatal 6-OHDA-treated rats, norepinephrine synthesized from L-dopa does not appear to contribute to the response. High doses of a decarboxylase inhibitor sufficient to inhibit conversion of dopa to dopamine in brain did not reduce the incidence of SMB. Administration of haloperidol (1 mg/kg) reduced the incidence of SMB, but did not antagonize the self-biting or the taffy pulling exhibited by L-dopa. In contrast, cisflupentixol completely blocked the SMB and self-biting induced by L-dopa.(ABSTRACT TRUNCATED AT 400 WORDS)

MeSH Terms
Age Factors Animals Antipsychotic Agents/pharmacology Aromatic Amino Acid Decarboxylase Inhibitors Behavior, Animal/drug effects Brain Chemistry/drug effects Dopamine/analysis Dopamine beta-Hydroxylase/antagonists & inhibitors Dose-Response Relationship, Drug Female Humans Hydroxydopamines/toxicity Lesch-Nyhan Syndrome/etiology Levodopa/pharmacology Motor Activity/drug effects Norepinephrine/analysis Oxidopamine Parkinson Disease, Secondary/etiology Rats Rats, Inbred Strains Receptors, Dopamine/drug effects Serotonin/analysis
Chemicals
Antipsychotic Agents Aromatic Amino Acid Decarboxylase Inhibitors Hydroxydopamines Receptors, Dopamine Serotonin Levodopa Oxidopamine Dopamine beta-Hydroxylase Dopamine Norepinephrine
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Breese G R
Baumeister A A
McCown T J
Emerick S G
Frye G D
Crotty K
Mueller R A
References (34)
34 references, click to expand
  1. Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine.
    Brain Res. 1973 Jun 15;55(2):369-82 PMID: 4145950
  2. Alterations in consummatory behavior following intracisternal injection of 6-hydroxydopamine.
    Pharmacol Biochem Behav. 1973 May-Jun;1(3):319-28 PMID: 4775860
  3. Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6-hydroxydopamine.
    Br J Pharmacol. 1972 Feb;44(2):210-22 PMID: 4148915
  4. Behavioral and prolactin responses to 5-hydroxytryptophan in rats treated during development with 5,7-dihydroxytryptamine.
    Brain Res. 1978 Oct 27;155(2):263-75 PMID: 308387
  5. Neurotransmitters and the Lesch-Nyhan syndrome.
    N Engl J Med. 1981 Nov 5;305(19):1148-50 PMID: 6117013
  6. Selective potentiation of locomotor effects of amphetamine by midbrain raphé lesions.
    Physiol Behav. 1972 Oct;9(4):655-7 PMID: 4670860
  7. Parkinson's disease: from brain homogenate to treatment.
    Fed Proc. 1973 Feb;32(2):183-90 PMID: 4143953
  8. Differential effects of para-chlorophenylalanine on amphetamine-induced locomotion and stereotypy.
    Brain Res. 1976 Nov 5;116(2):267-76 PMID: 135600
  9. Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system.
    Acta Physiol Scand Suppl. 1971;367:95-122 PMID: 4332694
  10. Effect of L-dopa on the locomotor activity of rats pretreated with 6-hydroxydopamine.
    Nat New Biol. 1971 Dec 1;234(48):157-9 PMID: 5289320
  11. Clinical, neuropathologic and pharmacologic aspects of Huntington's disease: correlates with a new animal model.
    Prog Neuropsychopharmacol. 1977;1(1-2):13-30 PMID: 214805
  12. Effects of L-dopa and L-5-hydroxytryptophan on locomotor activity of the rat after selective or combined destruction of central catecholamine and serotonin neurons.
    J Pharmacol Exp Ther. 1979 Nov;211(2):296-304 PMID: 315459
  13. L-Dopa-induced release of cerebral monoamines.
    Science. 1970 Oct 2;170(3953):76-7 PMID: 5452893
  14. Behavioral and biochemical interactions of 5,7-dihydroxytryptamine with various drugs when administered intracisternally to adult and developing rats.
    Brain Res. 1975 Nov 21;98(3):517-27 PMID: 1242372
  15. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.
    Acta Physiol Scand Suppl. 1971;367:69-93 PMID: 4332693
  16. Simultaneous quantification of dopamine, 5-hydroxytryptamine and four metabolically related compounds by means of reversed-phase high-performance liquid chromatography with electrochemical detection.
    J Chromatogr. 1981 Oct 9;225(2):347-57 PMID: 7298770
  17. Altered response to apomorphine in 6-hydroxydopamine-treated rats.
    Eur J Pharmacol. 1972 Jul;19(1):115-8 PMID: 5048659
  18. Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons.
    J Pharmacol Exp Ther. 1970 Sep;174(3):413-20 PMID: 5456173
  19. Hypoxanthine-guanine phosphoribosyltransferase deficiency. The molecular basis of the clinical syndromes.
    N Engl J Med. 1983 Oct 13;309(15):900-10 PMID: 6136913
  20. Biochemical and pharmacological differentiation of neuroleptic effect on dopamine D-1 and D-2 receptors.
    J Neural Transm Suppl. 1983;18:157-64 PMID: 6135740
  21. A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION.
    Am J Med. 1964 Apr;36:561-70 PMID: 14142409
  22. Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome.
    N Engl J Med. 1981 Nov 5;305(19):1106-11 PMID: 6117011
  23. Comparison of tyrosine hydroxylase and dopamine-beta-hydroxylase inhibition with the effects of various 6-hydroxydopamine treatments on d-amphetamine induced motor activity.
    Psychopharmacologia. 1974 Mar 21;36(1):1-16 PMID: 4151923
  24. Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats.
    Brain Res. 1984 Jan 16;291(1):164-7 PMID: 6199080
  25. Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine.
    Br J Pharmacol. 1974 Oct;52(2):307-314 PMID: 4155993
  26. Behavioral and biochemical studies of the scopolamine-induced reversal of neuroleptic activity.
    Psychopharmacology (Berl). 1981;73(1):17-22 PMID: 6112768
  27. Ontogeny of stereotyped behaviour induced by apomorphine and amphetamine in the rat.
    Arch Int Pharmacodyn Ther. 1973 Mar;202(1):171-82 PMID: 4694351
  28. Role of monoamine neural systems in L-dihydroxyphenylalanine-stimulated activity.
    J Pharmacol Exp Ther. 1979 Jan;208(1):37-43 PMID: 759613
  29. A simplified method of evaluating dose-effect experiments.
    J Pharmacol Exp Ther. 1949 Jun;96(2):99-113 PMID: 18152921
  30. Aromatic amino acid decarboxylase inhibitors.
    Fed Proc. 1971 May-Jun;30(3):871-6 PMID: 5575298
  31. Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: evidence for involvement of brain dopamine.
    J Pharmacol Exp Ther. 1973 Jun;185(3):609-19 PMID: 4145870
  32. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.
    J Pharmacol Exp Ther. 1983 Aug;226(2):462-8 PMID: 6135795
  33. Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis.
    Science. 1967 Mar 31;155(3770):1682-4 PMID: 6020292
  34. An inhibitory role for brain serotonin-containing systems in the locomotor effects of d-amphetamine.
    J Pharmacol Exp Ther. 1976 Jul;198(1):12-22 PMID: 132524
Article Info
Journal
The Journal of pharmacology and experimental therapeutics
Abbr.
J Pharmacol Exp Ther
ISSN
0022-3565
Published
1984-11-00
Pages
343-54
Language
English
Region
United States
NLM ID
0376362
PMCID
PMC3060042
Subset
IM
Grants
NHLBI NIH HHS · HL-31424 · United States
NICHD NIH HHS · P30 HD003110 · United States
NIMH NIH HHS · MH-36294 · United States
NICHD NIH HHS · HD-03110 · United States
NICHD NIH HHS · P30 HD003110-39 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com